Journal
ONCOGENE
Volume 31, Issue 32, Pages 3733-3740Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2011.542
Keywords
NPM-ALK; GSK3; ALCL; oncogenesis
Funding
- NIH [5R01CA140806-02, R01DE119249, R01CA136905]
Ask authors/readers for more resources
Anaplastic large cell lymphoma (ALCL) is the most common type of pediatric peripheral T-cell lymphoma. In 70-80% of cases, the chromosomal aberration t(2;5)(p23;q35) results in the juxtaposition of anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM) and the subsequent expression of the NPM-ALK fusion protein. NPM-ALK is a chimeric tyrosine kinase, which induces numerous signaling pathways that drive proliferation and abrogate apoptosis. However, the mechanisms that lead to activation of downstream growth regulatory molecules have not been completely elucidated. Using a mass spectrometry-based phosphoproteomic screen, we identified GSK3 beta as a signaling mediator of NPM-ALK. Using a selective inhibitor of ALK, we demonstrated that the tyrosine kinase activity of ALK regulates the serine-9 phosphorylation of GSK3 beta. Expression of NPM-ALK in 293T cells led to an increase of pS(9)-GSK3 beta (glycogen synthase kinase 3 beta) compared with kinase-defective K210R mutant NPM-ALK, but did not affect total GSK3 beta levels. Phosphorylation of pS(9)-GSK3 beta by NPM-ALK was mediated by the PI3K/AKT signaling pathway. ALK inhibition resulted in degradation of GSK3 beta substrates Mcl-1 and CDC25A, which was recovered upon chemical inhibition of the proteasome (MG132). Furthermore, the degradation of Mcl-1 was recoverable with inhibition of GSK3 beta. ALK inhibition also resulted in decreased cell viability, which was rescued by GSK3 beta inhibition. Furthermore, stable knockdown of GSK3 beta conferred resistance to the growth inhibitory effects of ALK inhibition using viability and colony formation assays. pS(9)-GSK3 beta and CDC25A were selectively expressed in neoplastic cells of ALK + ALCL tissue biopsies, and showed a significant correlation (P<0.001). Conversely, ALK-ALCL tissue biopsies did not show significant correlation of pS(9)-GSK3 beta and CDC25A expression (P<0.2). Our results demonstrate that NPM-ALK regulates the phosphorylation of S-9-GSK3 beta by PI3K/AKT. The subsequent inhibition of GSK3 beta activity results in accumulation of CDC25A and Mcl-1, which confers the advantage of growth and protection from apoptosis. These findings provide support for the role of GSK3 beta as a mediator of NPM-ALK oncogenesis. Oncogene (2012) 31, 3733-3740; doi:10.1038/onc.2011.542; published online 19 December 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available